BMS-986213 (Relatlimab-Nivolumab FDC)

DRUG2 trials

Sponsors

M.D. Anderson Cancer Center

Conditions

Melanoma (Skin)Renal Cell Carcinoma, Clear Cell

Phase 2

Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases

RecruitingNCT05704647

M.D. Anderson Cancer CenterMelanoma (Skin)

Start: 2023-02-23End: 2028-07-31Target: 30Updated: 2026-07-16

A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)

Active, not recruitingNCT06708949

M.D. Anderson Cancer CenterRenal Cell Carcinoma, Clear Cell

Start: 2025-03-20End: 2028-12-15Updated: 2026-09-11

Related Papers

Phase II study of nivolumab (nivo) in combination with relatlimab (rela) in patients (pts) with active melanoma brain metastases (MBM).

Journal of Clinical Oncology2023-06-016 citations